Effects of Tirzepatide on Blood, Imaging and Breast Tissue Biomarkers

Part of paid clinical trials in Kansas City, Kansas.

Sponsor
University of Kansas Medical Center
Study ID
NCT06485089
Status
Completed

Conditions

Eligibility Criteria

Sex
FEMALE
Age
40 Years - 64 Years
Healthy Volunteers
Accepted

Interventions

  • tirzepatide — DRUG
    Women taking tirzepatide as part of standard care in the Weight Managment Clinic

Study Details

Evaluation of biomarkers for risk of developing breast cancer in women with obesity who are using tirzepatide to achieve weight loss.

Key Dates

Start date
Sep 14, 2024
Status verified
Oct 2025
Primary completion
Mar 25, 2026
Completion
Mar 25, 2026

Study Design

Enrollment
25 participants (actual)

Arms

  • Arm: women using tirzepatide for weight loss
    Women attending the University of Kansas Medical Center (KUMC) Weight Management Clinic

Primary Outcome Measure

Feasibility of design as assessed by accrual rate of 1 or more per month over 12 months [ Time Frame: 12 months ]

Locations (2)

FacilityCityStateZIPSite coordinators
University of Kansas Medical CenterKansas CityKansas66160-
University of Kansas Medical Center Breast Cancer Prevention CenterWestwoodKansas66208-

Find similar trials in Kansas City, KS

By condition
Obesity / overweight
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
University of Kansas Medical Center· Kansas City, KSUniversity of Kansas Medical Center Breast Cancer Prevention Center· Westwood, KS

Related Studies